Clinical Trials Directory

Trials / Unknown

UnknownNCT02855632

The Efficacy of G-CSF Against Adhesion Reformation After Hysteroscopic Adhesiolysis

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
240 (estimated)
Sponsor
Sir Run Run Shaw Hospital · Academic / Other
Sex
Female
Age
18 Years – 40 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to investigate the efficacy of Granulocyte Colony Stimulating Factor(G-CSF) on decreasing adhesion reformation and improving fertility outcomes after hysteroscopic adhesiolysis in patients with moderate to severe intrauterine adhesions.

Detailed description

After hysteroscopic adhesiolysis, patients with moderate to severe intrauterine adhesions will be allocated into 2 groups randomly, with COOK ballon and estrogen and progesterone sequential therapy given to prevent adhesion routinely. 7 day later, G-CSF or normal saline will be injected into the uterine cavity by Tom catheter after removing the balloon respectively. A second hysteroscopic examination will be performed in 2 months to check up the adhesion reformation. In addition, the endometrial thickness after surgery and fertility outcome will be followed up.

Conditions

Interventions

TypeNameDescription
DRUGG-CSF7 days after first hysteroscopic adhesiolysis, G-CSF will be injected into the uterine cavity after balloon removing.
DRUGNormal saline7 days after first hysteroscopic adhesiolysis, normal saline will be injected into the uterine cavity after balloon removing.
DRUGhormone therapyIn all cases hormone therapy was commenced shortly after the operation, consisting of oestradiol valerate at a dose of 6 mg per day for 21-28 days with the addition of medroxyprogesterone acetate at a dose of 6 mg per day for the last 7-10 days of the oestrogen therapy. Following the withdrawal bleed, the hormone therapy was repeated for another cycle.
OTHERCook balloonAt the end of the procedure, the Cook balloon were placed in the uterine cavity of each patient.the device was removed after 7 days.

Timeline

Start date
2016-08-01
Primary completion
2018-12-01
Completion
2019-12-01
First posted
2016-08-04
Last updated
2018-01-05

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT02855632. Inclusion in this directory is not an endorsement.